- Home
- ACIU vs MTA Comparison
ACIU vs MTA Comparison
Compare ACIU & MTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- MTA
- Stock Information
- Founded
- ACIU 2003
- MTA 1983
- Country
- ACIU Switzerland
- MTA Canada
- Employees
- ACIU N/A
- MTA N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- MTA
- Sector
- ACIU Health Care
- MTA
- Exchange
- ACIU Nasdaq
- MTA Nasdaq
- Market Cap
- ACIU 270.1M
- MTA 267.2M
- IPO Year
- ACIU 2016
- MTA N/A
- Fundamental
- Price
- ACIU $2.65
- MTA $2.97
- Analyst Decision
- ACIU Strong Buy
- MTA Hold
- Analyst Count
- ACIU 2
- MTA 1
- Target Price
- ACIU $12.00
- MTA $4.50
- AVG Volume (30 Days)
- ACIU 203.0K
- MTA 309.1K
- Earning Date
- ACIU 03-13-2025
- MTA 03-27-2025
- Dividend Yield
- ACIU N/A
- MTA N/A
- EPS Growth
- ACIU N/A
- MTA N/A
- EPS
- ACIU N/A
- MTA N/A
- Revenue
- ACIU $48,505,404.00
- MTA $5,048,000.00
- Revenue This Year
- ACIU $86.78
- MTA $37.69
- Revenue Next Year
- ACIU $118.22
- MTA $120.61
- P/E Ratio
- ACIU N/A
- MTA N/A
- Revenue Growth
- ACIU 4097200.00
- MTA 28.55
- 52 Week Low
- ACIU $2.25
- MTA $2.32
- 52 Week High
- ACIU $4.98
- MTA $4.08
- Technical
- Relative Strength Index (RSI)
- ACIU 47.51
- MTA 47.34
- Support Level
- ACIU $2.39
- MTA $3.08
- Resistance Level
- ACIU $2.74
- MTA $3.40
- Average True Range (ATR)
- ACIU 0.14
- MTA 0.13
- MACD
- ACIU 0.01
- MTA -0.02
- Stochastic Oscillator
- ACIU 56.52
- MTA 23.21
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About MTA Metalla Royalty & Streaming Ltd.
Metalla Royalty & Streaming Ltd is a precious metals royalty and streaming company, which engages in the acquisition and management of precious metal royalties, streams, and similar production-based interests. It's a pure-play gold and silver streaming and royalty company. It generates revenue from royalties, streams, and other interests.